Norvasc to get 29% market shares of Calcium blockers in 3Q

Pfizer Korea's Norvasc (amlodipine besylate), an antihypertension drug, has achieved a successful sale of this year, showing the top place at about 41% of market shares out of the total anti-hypertension drugs or 29% out of the total calcium channel blockers during the 3rd quarter this year. The top amlodipine salt product showed 7% of market shares and others less than 7%.

Pfizer Korea sai...